2023 World Conference on Lung Cancer (Posters)-P2.07. Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer

P2.07. Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the factors associated with disease progression after discontinuation of immunotherapy for immune-related toxicity in non-small cell lung cancer (NSCLC). The clinicopathologic data of patients with advanced NSCLC who received immune checkpoint inhibitors (ICI) and discontinued treatment due to immune-related adverse events (irAEs) were analyzed. Post-discontinuation progression-free survival (PFS) and overall survival (OS) were evaluated.<br /><br />The study cohort consisted of 271 patients, with a median age of 69. Most patients were males (43.5%) and had a history of autoimmune disease (6.3%). The majority of patients had non-squamous histology (84.9%) and a PD-L1 tumor proportion score of 50% (62.3%). The median treatment duration before discontinuation was 5.9 months.<br /><br />The results showed that patients who were treated with ICI for at least 6 months before discontinuation had prolonged disease control without further treatment. Patients who achieved a complete or partial response as the best overall response also had better outcomes after discontinuation. The duration of treatment with ICI was a significant predictor of post-discontinuation PFS and OS.<br /><br />Furthermore, the study analyzed the clinical outcomes of patients who underwent rechallenge with ICI after disease progression. The results showed that some patients experienced disease control and prolonged survival with rechallenge.<br /><br />In conclusion, this study demonstrates that prolonged disease control can be achieved without further treatment in patients with advanced NSCLC who discontinue ICI due to immune-related toxicity, especially those treated for at least 6 months and achieved a complete or partial response. These findings provide valuable insights into the management of irAEs and the optimization of treatment strategies in NSCLC patients receiving immunotherapy.

Asset Subtitle

Biagio Ricciuti

Meta Tag

Speaker Biagio Ricciuti

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

disease progression

immunotherapy

immune-related toxicity

non-small cell lung cancer

NSCLC

immune checkpoint inhibitors

irAEs

progression-free survival

overall survival

clinicopathologic data